1310383-72-2

Basic information

• Product Name: (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate
• Synonyms: (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate;Bortezomib Impurity 32
• CAS NO: 1310383-72-2
• Molecular Formula: C17H31BF3NO5
• Molecular Weight: 397.2379496
• Mol File: 1310383-72-2.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate(1310383-72-2)
• EPA Substance Registry System: (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate(1310383-72-2)

Safety Data

• Hazardous Substances Data: 1310383-72-2(Hazardous Substances Data)

Usage

Description

(R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate is a complex organic compound with a unique molecular structure. It is characterized by its chiral center at the 3rd carbon, which is in the R configuration. The compound also features a boron-containing heterocycle, which is derived from a benzo[d][1,3,2]dioxaborole framework. This structure is further modified by various methyl groups and a 2,2,2-trifluoroacetate group, which may contribute to its potential applications in various fields.

Uses

Used in Pharmaceutical Industry:
(R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs, particularly those targeting proteasomes.
Used in Chemical Research:
In the field of chemical research, this compound can be used as a starting material or a reagent for the synthesis of more complex molecules. Its chiral center and boron-containing heterocycle may be of interest to researchers studying asymmetric synthesis, organoboron chemistry, and the development of novel catalysts or ligands.
Used in Material Science:
The unique structure of (R)-3-Methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butan-1-amine 2,2,2-trifluoroacetate hydrate may also find applications in material science. Its properties, such as its potential to form self-assembled structures or its interaction with other molecules, could be exploited to create new materials with specific properties, such as improved conductivity, stability, or selectivity.

Upstream product

• 1135491-84-7 (1S)-(S)-pinanediol 1-bis(trimethylsilyl)amino-3-methylbutane-1-boronate 
• 76-05-1 trifluoroacetic acid 
• 514820-48-5 1,1,1-trimethyl-N-{(1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}-N-(trimethylsilyl)silanamine 
• 84110-34-9 2-(2-methylpropyl)-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole 
• 18680-27-8 pinanediol 
• 87249-60-3 (3aS,4S,6S,7aR)-2-(dichloromethyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole 
• 85167-14-2 (3aS,4S,6S,7aR)-2-[(1S)-1-chloro-3-methylbutyl]-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborole 
• 179324-86-8 (1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0^2,6]decan-4-yl]butan-1-amine 
• 4111-54-0 lithium diisopropyl amide 
• 108-18-9 diisopropylamine 
• 22422-34-0 (1R,2R,3S,5R)-2,3-pinane diol 
• 1173167-09-3 2-methyl-4-chloro-butylboronic acid-(-)-α-pinanediol ester 

Downstream Products

• 1384596-12-6 N-(4-nicotin)carbonyl-L-phenylalanine-L-leucineboronic acid 
• 1384596-13-7 N-(-2-thiophene)carbonyl-L-phenylalanine-L-leucineboronic acid 
• 1384596-16-0 N-(2-tetrahydrofuran)carbonyl-L-phenylalanine-L-leucineboronic acid 
• 1384596-07-9 N-(tryptophan)carbonyl-L-phenylalanine-L-leucineboronic acid 
• 1384596-10-4 C₁₉H₃₀BN₃O₄ 
• 1443646-22-7 C₂₈H₃₈BN₃O₄ 
• 179324-69-7 velcade 

Relevant articles and documents

De Novo Design of Boron-Based Peptidomimetics as Potent Inhibitors of Human ClpP in the Presence of Human ClpX

Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron's ability to modulate enzyme function. Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and a virtual screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.

Preparation of (1R)-(S)-pinane diol-1-amino-3-methyl-butane-1-borate and a salt thereof

The invention discloses a method for preparing (1R)-(S)-pinanediol-1-amino-3-methylbutane-1-borate ester and a salt thereof. The method for preparing (1R)-(S)-pinanediol-1-amino-3-methylbutane-1-borate ester comprises step A and step B in the following synthetic route, wherein in the formula, X represents a halogen atom and M represents an alkali metal. (1R)-(S)-pinanediol-1-amino-3-methylbutane-1-borate ester is subjected to a salt forming reaction with an organic acid or an inorganic aid, and an acidic salt of (1R)-(S)-pinanediol-1-amino-3-methylbutane-1-borate ester is obtained. The method of the invention can help to synthesize high-purity bortezomib or other boropeptide compounds in low cost, is accord with industrial production requirements and has practical value.

Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif

The ubiquitin-proteasome system (UPS) has been successfully targeted by both academia and the pharmaceutical industry for oncological and immunological applications. Typical proteasome inhibitors are based on a peptidic backbone endowed with an electrophi